Once-a-Day HAART: Dream or Reality?

REFERENCES

• Lucas GN, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81–87.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Hecht FM, Swanson M, et al. HIV-RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS. 1999;13:F35–F43.
   PubMed Web of Science ®Google Scholar
• Fischl M, Castro J, Monroig R, et al. Impact of directly observed therapy on long-term outcomes in HIV clinical trials. In: Program and abstracts of the 8th CROI; February 2001; Chicago, IL. Abstract 528.
   Google Scholar
• Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.
   PubMed Web of Science ®Google Scholar
• Ostrow D, Fox K, Kleenberger C, et al. Psychosocial corre-lates of incomplete adherence to HIV antiretroviral therapy (HAART): mental health matters. In: Program and abstracts of the 8th CROI; February 2001; Chicago, IL. Abstract 484.
   Google Scholar
• Gordillo V, del Arno J, Soriano V, Gonzalez-Lahov J. Sociodemographic and psychological variables influenc-ing adherence to antiretroviral therapy. AIDS. 1999;13:1763–1769.
   PubMed Web of Science ®Google Scholar
• Stone VE, Adelson-Mitty J, Arnstern JH, Davenny K, Schoenbaum EE. What strategies do providers use to en-hance adherence to HAART? In: Program and abstracts of the 13th International Conference on AIDS; July 2000; Durban, South Africa. Abstract ThPeB5027.
   Google Scholar
• Stone VE, Clarke J, Lovell J, et al. HIV/AIDS patients' perspectives on adhering to regimens containing protease inhibitors. J Gen Intern Med. 1998;13:586–593.
   PubMed Web of Science ®Google Scholar
• Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS. 2001;15:1369–1377.
   PubMed Web of Science ®Google Scholar
• Jordan J, Rosenzweig J, Athnak D, et al. Perceived influ-ence of regimen characteristics on adherence. In: Program and abstracts of the 5th International Congress on Drug Therapy in HIV Infection; October 2000; Glasgow, Scot-land. Abstract 121.
   Google Scholar
• Bass D, Smith M. HIV patients prefer once-daily regimens. In: Program and abstracts of the 14th International Confer-ence on AIDS; July 2002; Barcelona, Spain. Abstract MoPeB3290.
   Google Scholar
• Papatheofanis FJ, Mukherjee J, Tuomari AV, Jackson S. HIV patients prefer once-daily dosing of antiretroviral medi-cation. In: Program and abstracts of the 14th International Conference on AIDS; July 2002; Barcelona, Spain. Ab-stract M0PeB3287.
   Google Scholar
• Moyle G. The APPT-1 study: assessing patients' preferred treatments. In: Program and abstracts of the 6th Interna-tional Congress on Drug Therapy in HIV Infection; October 2002; Glasgow, Scotland. Abstract 99.
   Google Scholar
• Mobley JE, Pollard RB, Schrader S, Adler MH, Kelleher T, McLaren C, and the A1454-143 Team. Virological and im-munological responses to once-daily dosing of didanosine in combination with stavudine. AIDS. 1999;13:F87–F93.
   PubMed Web of Science ®Google Scholar
• Moore KHP, Barrett JE, Shaw S, et al. The pharmacokinet-ics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS. 1999;13:2239–2250.
   PubMed Web of Science ®Google Scholar
• Baril JG, Pollard RB, Raffi F, et al. Stavudine extemded/ prolonged release (XR/PRC) versus stavudine immediate release (IR) in combination with lamivudine and efavirenz: 48 week efficacy and safety. In: Program and abstracts of the 14th International Conference on AIDS; July 2002; Barcelona, Spain. Abstract LBPeB9014.
   Google Scholar
• Bowonwatanuwong C, Mootsikapun P, Supparatpinyo K, et al. A randomized, open label study to investigate abacavir and lamivudine as once daily components of a triple combination regimen. In: Program and abstracts of the 1st IAS; July 2001; Buenos Aires, Argentina. Ab-stract 4.
   Google Scholar
• Kearney BP, Flaherty JF, Sayre JR, et al. Effect of formula-tions and food on the pharmacokinetics of tenofovir DF. In: Program and abstracts of the 2nd International Workshop on Clinical Pharmacology of HIV Therapy; April 2001; Noordwijk, the Nederlands. Abstract 3,18.
   Google Scholar
• Pozniak A, Staszewski S, Gallant J, et al. Comparison of the efficacy and safety of tenofovir disoproxil fumarete (TDF) versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavirenz (EFV) in HIV-1 infected patients naive to antiretroviral therapy (ART) after 48 weeks of treatment. In: Program and abstracts of the 6th Interna-tional Congress on Drug Therapy in HIV Infection; October 2002; Glasgow, Scotland. Abstract P1.
   Google Scholar
• Kearney BP, Flaherty JF, Wolf J, et al. Coadministration of tenofovir DF and didanosine: pharmacokinetic drug-drug interaction and safety evaluation. In: Program and ab-stracts of the 8th ECCATHI; October 2001; Athens, Greece. Abstract 172.
   Google Scholar
• Kearney BP, Isaacson E, Sayre J, Namini H, Cheng A. Didanosine and tenofovir DF drug-drug interaction: as-sessment of didanosine dose reduction. In: Program and abstracts of the 10th CROI; February 2003; Boston, MA. Abstract 533.
   Google Scholar
• Zeier M, Sanne I, Van Der Berg M, Quinn J, Shaw A. Efficacy and safety of emtricitabine (FTC) triple combina-tion therapy in HIV-1 infected treatment-naive male and female patients. In: Program and abstracts of the 41st ICAAC; December 2001; Chicago, IL. Abstract 1–1933.
   Google Scholar
• Joshi AS, Barrett JS, Fiske WD, et al. Population pharma-cokinetics of efavirenz in phase 11 studies and relationship with efficacy. In: Program and abstracts of the 39th ICAAC; September 1999; San Francisco, CA. Abstract 1201.
   Google Scholar
• Van Heeswijk RP, Veldkamp Al, Mulder JW, et al. The steady state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS. 2000;14:F77–F82.
   PubMed Web of Science ®Google Scholar
• Garcia F, Knobel H, Sambeat MA, et al. Comparison of twice daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the Scan Study. AIDS. 2000,14:2485–2494.
   PubMed Web of Science ®Google Scholar
• Raffi F, Reliquet V, Ferre V, et al. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1 infected adults. Antiviral Ther. 2000;5:267–272.
   PubMed Web of Science ®Google Scholar
• Murphy RL, Katlama C, Johnson V, et al. The Atlantic Study: a randomized, open-label trial comparing two pro-tease inhibitor (PI)-sparing antiretroviral strategies versus a standard P1-containing regimen. 48-week results. In: Pro-gram and abstracts of the 39th ICAAC; September 1999; San Francisco, CA. Abstract LB2.
   Google Scholar
• Van Leth F, Hassink E, Phanuphak P, et al. Results of the 2NN study: a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine. In: Program and abstracts of the 10th CROI; February 2003; Boston, MA. Abstract 176.
   Google Scholar
• Kurowski M, Staszewski S, Arslan A, et al. Influence of 50 mg, 100 mg and 200 mg ritonavir (RTV) on the pharmacoki-netics (PK) of amprenavir (APV) after multiple doses in healthy volunteers for once daily (QD) and twice daily (BID) regimens. In: Program and abstracts of the 1st IAS; July 2001; Buenos Aires, Argentina. Abstract 351.
   Google Scholar
• Arasteh K, Wood R, Teofilo E, et al. Amprenavir (APV) 600 mg/ritonavir (RTV) 100 mg BID or APV 1200 mg/RTV 200 mg QD given in combination with abacavir (ABC) and lamivudine (3TC) maintains efficacy in ART naive HIV-1 infected adults over 24 weeks (APV20001). In: Program and abstracts of the 8th ECCATHI; October 2001; Athens, Greece. Abstract 218.
   Google Scholar
• Maggiolo F, Rizzi M, Finazzi G, Suter F. Once-a-day indinavir therapy in virologically controlled HIV+ persons. In: Program and abstracts of the 13th International Confer-ence on AIDS; July 2000; Durban, South Africa. Abstract TuPpA1155.
   Google Scholar
• Suleiman J, Rhodes R, Campo R, et al. Preliminary results from indinavir (IDV) and ritonavir (RTV) in a once-daily regimen. In: Program and abstracts of the 8th CROI; Feb-ruary 2001; Chicago, IL. Abstract 336.
   Google Scholar
• Montaner JSG, Saag M, Schwartz R. Pharmacokinetic and safety evaluations of a once daily regimen of saquinavir soft gel (SQV) in HIV infected anti-retroviral naive patients. In: Program and abstracts of the Frontiers in Drug Develop-ment for Antiretroviral Therapies; December 2000; San Juan, Puerto Rico. Abstract 48.
   Google Scholar
• Hsyu PH, Lewis R, Tran J, et al. Pharmacokinetics (PK) of nelfinavir (NFV) after once-daily dosing in combination with mini-doses of ritonavir (RTV) in healthy subjects. In: Pro-gram and abstracts of the 13th International Conference on AIDS; July 2000; Durban, South Africa. Abstract LbPeB7049.
   Google Scholar
• Cardiello P, Van Heeswijk R, Monhaphol T, et al. HIV-NAT 001.3: the safety, efficacy and pharmacokinetics (PK) of 1600 mg saquinavir (soft gelatin capsules; SQV-SGC) plus low dose ritonavir (RTV, 100 mg) in a once-daily (qd) dosing regimen in HIV-infected Thai patients. In: Program and abstracts of the 1st IAS; July 2001; Buenos Aires, Argen-tina. Abstract 59.
   Google Scholar
• Eron J, Bernstein B, King M, et al. Once-daily versus twice daily Kaletra (lopinavir/ritonavir) in antiretroviral-naive HIV+ patients: 48 week follow-up. In: Program and abstracts of the 9th CROI; February 2002; Seattle, WA. Abstract 409.
   Google Scholar
• Squires KE, Thiry A, Giordano M, et al. Atazanavir (ATV) QD vs efavirenz (EFV) QD with fixed-dose ZDV + 3TC BID: comparison of antiviral efficacy and safety. In: Program and abstracts of the 42nd ICAAC; September 2002; San Diego, CA. Abstract 1076.
   Google Scholar
• Schuermann D, Gathe J, Sanne I, Wood R, on behalf of the SOLO study team. Efficacy and safety of GW433908/ ritonavir once daily in therapy-naive subjects, 48 week results: the SOLO study. In: Program and abstracts of the 6th International Congress on Drug Therapy in HIV Infec-tion; October 2002; Glasgow, Scotland. Abstract PL 14.4.
   Google Scholar
• Staszewski S, Haberl A, Gute P, et al. Nevirapine/ didanosine/lamivudine once daily in HIV-1-infected intra-venous drug users. Antiviral Ther. 1998;3\(suppl 4):55–56.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Migliorino M, Maserati R, et al. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antivi-ral Ther. 2001;6:249–253.
   PubMed Web of Science ®Google Scholar
• Landman R, Thiam S, Canestri A, et al. Long term evalua-tion (15 months) of ddl, 3TC and efavirenz once daily regimen in naive patients in Senegal: ANRS 12-04/IMEA 011 study. In: Program and abstracts of the 9th CROI; February 2002; Seattle, WA. Abstract 458.
   Google Scholar
• Molina JM, Ferchal F, Jounot V, et al. Once-daily combina-tion therapy with emtricitabine, didanosine and efavirenz in treatment naive HIV-infected adults: 96-week follow-up of the ANRS 091 trial. In: Program and abstracts of the 8th ECCATHI; October 2001; Athens, Greece. Abstract 221.
   Google Scholar
• Jordan W, Jefferson R, Yemofio F, et al. Nevirapine (NVP) + efavirenz (EFV) + didanosine (ddl): a very simple, safe, and effective once-daily regimen. In: Program and abstracts of the 13th International Conference on AIDS; July 2000; Durban, South Africa. Abstract TuPeB3207.
   Google Scholar
• Mole L, Schmidgall D, Holodniy M. A pilot trial of indinavir, ritonavir, didanosine and lamivudine in a once-daily four-drug regimen for HIV infection. J Acquir Immune Defic Syndr. 2001;27:260–265.
   PubMed Web of Science ®Google Scholar
• Hsieh SM, Hung CC, Lu PL, Chen MY, Chang SC. Prelimi-nary experience of adverse drug reactions, tolerability and efficacy of a once-daily regimen of antiretroviral combina-tion therapy. J Acquir Immune Defic Syndr. 2000;24:287–288.
   PubMed Web of Science ®Google Scholar
• Skowron G, Kuritzkes DR, Thompson MA, et al. Once-daily quadruple drug therapy with adefovir dipivoxil, lamivudine, didanosine and efavirenz in treatment-naive human immu-nodeficiency virus type 1-infected patients. J Infect Dis. 2002;186:1028–1033.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Arici C, Gregis G, et al. A controlled, random-ized, prospective study on a once-a-day therapy for HIV infection. In: Program and abstracts of the 42nd ICAAC; September 2002; San Diego, CA. Abstract H–163.
   Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–1310.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Ripamonti D, Arici C, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clin Trials. 2002;5: 371–378.
   Google Scholar
• Fauci AS, Bartlett JG, Goosby EP, et al. Guidelines for the use of antiretroviral agents in HIV-infected adults and ado-lescents. MMWR 1998; 47 (N° rr-5). Updated as a living document on February 4, 2002. Available from the HIV/ AIDS treatment information service, www.hivatis.org
   Google Scholar
• Conway B, Prasad J, Smith N, de Vlaming S. Once-daily vs. twice-daily directly observed (DOT) for management of HIV-infected individuals in a methadone program. In: Pro-gram and abstracts of the 41st ICAAC; December 2001; Chicago, IL. Abstract 1917.
   Google Scholar
• Dybul M, Yoder C, Belson M, et al. Short cycle intermittent HAART: a pilot study. In: Program and abstracts of the 13th International Conference on AIDS; July 2000; Durban, South Africa. Abstract LbOr12.
   Google Scholar
• Back D, Gatti G, Fletcher C, et al. Therapeutic drug moni-toring in HIV infection: current status and future directions. AIDS. 2002:16\(suppl 1):55–537.
   Google Scholar